Vascular Pathways

About Vascular Pathways

Vascular Pathways, Inc. was a medical device company established in 2005 with a focus on developing and marketing advanced vascular access devices. The company was founded by Dr. Amir Belson, a serial entrepreneur in the medical technology space who has founded multiple successful companies that were later acquired. Dr. Belson's background includes a medical degree from the Technion, Israel Institute of Technology, a pediatric residency, and a pediatric nephrology fellowship at Stanford University, followed by a research fellowship in Stanford's Biomedical Technology Innovation Program. This foundation in medicine and biomedical innovation directly influenced the company's direction.

The firm's core business centered on the commercialization of its flagship product, the AccuCath™ Intravenous (IV) Catheter System. This system was engineered to improve the success rate of peripheral IV placements, particularly in patients with difficult intravenous access (DIVA). The business model revolved around selling these proprietary catheter systems to healthcare providers, such as hospitals and clinics, aiming to reduce multiple insertion attempts, decrease patient discomfort, and lower overall healthcare costs.

The AccuCath™ system's key feature was its integrated use of a coiled-tip Nitinol guidewire, a material known for its flexibility and kink resistance. This guidewire technology was designed to help clinicians navigate vasculature more effectively, increasing the likelihood of successful first-attempt insertions, especially in deeper vessels. The catheters also incorporated features like a blood control valve to minimize blood exposure and needlestick safety mechanisms. The product line included various lengths, such as 2.25-inch and 3.1-inch versions, to address different clinical needs, including venous and arterial applications for patients ranging from bariatric to those with other challenging vascular conditions. Over its operational years, Vascular Pathways secured significant funding, raising a total of $19.5 million across several rounds from investors including CHL Medical Partners, MVM, Ascension Ventures, and Square 1 Bank. A major milestone was achieved on July 1, 2015, when the company was acquired by C.R. Bard, which subsequently integrated Vascular Pathways' technology and product lines.